Dotarem (gadoterate meglumine) / Guerbet - LARVOL DELTA

PET/MRI imaging in an intracranial tumour model to assess uptake of 89 Zr-Df-ifabotuzumabpyrrolobenzodiazepine across the blood brain barrier (EANM 2026) - "3T MRI (nanoScan, Mediso, Hungary) was used to measure tumour growth weekly using Dotarem contrast agent. An orthotopic human GBM tumour model in BALB/c nude mice showed comparable tumour uptake between 89Zr-Df-ifabotuzumab and 89Zr-Dfifabotuzumab-PBD. This model offers a great opportunity to study the conditions that allow ifabotuzumab-ADCs and other payloads (225Ac-ifabotumumab) to cross the blood brain barrier. Future studies will include: PET/MRI with a 89Zr-labelled IgG control antibody to assess specificity, tumour uptake in 20-40 mm3 subcutaneous U251 xenografts, and investigating an EphA3- murine GBM model (GL261) to examine orthotopic TME uptake."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • EPHA3

Oxaliplatin-Associated Focal Nodular Hyperplasia (ACG 2026) - "Case Description/ A 44-year-old man with a past medical of invasive rectal adenocarcinoma cT32N2aM0, stage IIIB was treated with four cycles of oxaliplatin, leucovorin, fluorouracil, neoadjuvant capecitabine, and eventual rectosigmoid resection...MRI with gadoterate meglumine was done to further evaluate the lesions...(20x, H&E) Liver biopsy showing a hepatocellular proliferation composed of benign-appearing hepatocytes arranged in expanded plates with mild cytoplasmic eosinophilia and focal sinusoidal dilatation/congestion in a background of subtle vascular alteration, consistent with focal nodular hyperplasiaâlike change. Inset: Glutamine synthetase immunohistochemical stain demonstrates characteristic map-like staining pattern supporting the diagnosis of focal nodular hyperplasia."

Colorectal Adenocarcinoma • Colorectal Cancer • Eosinophilia • Hepatocellular Cancer • Hepatology • Liver Failure • Rectal Adenocarcinoma • Solid Tumor • CTNNB1 • GPC3

No evidence of major integrative brain clearance impairment in an Alzheimer´s disease model of transgenic APPswe/PS1dE9 mice. (PubMed, Fluids Barriers CNS) - "Our findings indicate that the APPswe/PS1dE9 mouse model does not exhibit evidence of major integrative brain clearance impairment, despite this being a hallmark of sporadic AD in humans. These results suggest limitations of this model for studying clearance-related mechanisms of late-onset AD, which should be acknowledged when planning future studies using this murine model."

Journal • Preclinical • Alzheimer's Disease • Amyloidosis • Anesthesia • CNS Disorders • Inflammation • OCLN

Optimisation of intra-articular contrast agent and acquisition parameters for contrast-enhanced microCT of the mouse knee. (PubMed, Bone) - "Two commercially available anionic gadolinium-based contrast agents (Dotarem and Magnevist) were first compared using intra-articular injection...Among the tested protocols, imaging at 70 kV, 114 μA, 1000 projections, and 200 ms integration time provided the most practical balance between image quality and scan duration. Together, this study identifies a practical contrast-enhanced microCT protocol for the in situ mouse knee that enhances joint-space contrast while maintaining compatibility with quantitative bone morphometry, providing a basis for future preclinical studies of osteoarthritis."

Journal • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology

Magnetic resonance and X-ray contrast agents in the optical clearing of dermis - insights from ex vivo confocal Raman micro-spectroscopy. (PubMed, Biomed Opt Express) - "By analysing Raman bands at 1003 and 1663 cm-1 and applying Fick's second law model, we calculated the diffusion coefficients of 3.51 × 10-8 cm2/s for Gadovist and 3.20 × 10-7 cm2/s for Omnipaque, with a slower diffusion regime for Dotarem...Autofluorescence enhancement scaled with diffusion-driven refractive index matching, confirming that optical clearing is mechanistically coupled to molecular transport; it may also arise from protein structural modifications, oxidative stress, or increased protein density following contrast agent interaction. Together, these findings establish a quantitative link between contrast-agent diffusivity, dermal penetration depth, optical transparency, and tissue autofluorescence, providing a framework for integrating Raman, MR, and X-ray modalities in multimodal depth-resolved skin imaging."

Journal • Preclinical

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (clinicaltrials.gov) - P3 | N=315 | Recruiting | Sponsor: Guerbet | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2026 ➔ Jul 2026

Enrollment open • Trial initiation date • Cardiovascular

A new HPLC-ICP-MS method for gadolinium speciation in freshwaters using ion exchange chromatography and aqueous mobile phases. (PubMed, Talanta) - "Among the analyzed freshwater samples, Dotarem was the only compound consistently detected. This study underscores the method's potential for widespread applicability in environmental monitoring and its contribution to the growing demand for sustainable analytical practices."

Journal

Acoustic Drug Delivery in Brain Tumors: Differential Impact of FUS Protocols on Healthy Brain Tissue and Induction of Neuronal and Astrocytic Apoptosis. (EACR 2026) - "T1-weighted (T1-w) MRI was acquired before and after gadolinium (Gd, Dotarem®) injection to confirm BBB opening in each region... Optimizing acoustic parameters is essential to maximize drug delivery while preserving healthy brain tissue. Our results demonstrate that, with SonoVue® MBs, acoustic pressures up to 0.60 MPa allow effective BBB opening without inducing hemorrhage or detectable apoptosis at the acute 1.5-hour time point. Higher pressures are associated with early apoptotic activation in neurons and astrocytes, as well as a risk of hemorrhagic events."

Clinical • Brain Cancer • Glioblastoma • Hematological Disorders • Oncology • Solid Tumor • CASP3 • GFAP

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas (clinicaltrials.gov) - P=N/A | N=4 | Completed | Sponsor: OHSU Knight Cancer Institute | Recruiting ➔ Completed | N=20 ➔ 4

Enrollment change • Trial completion • Brain Cancer • CNS Disorders • Glioma • Oncology • Solid Tumor

Glymphatic System Visualized With Intrathecal Gadoterate Meglumine Administered via External Ventricular Drain. (PubMed, Cureus) - "While low-dose IT gadolinium administration has demonstrated tolerability in prior human studies, the present findings highlight that definitive conclusions regarding safety and causality cannot be drawn from this small cohort. These results support the feasibility of IT contrast-enhanced MRI for evaluating glymphatic function, but larger prospective studies are needed to better define safety, pathophysiological mechanisms, and clinical implications."

Journal • CNS Disorders • Vascular Neurology

Contrast-induced changes in chemical exchange saturation transfer MRI differentiate tumor progression from pseudoprogression. (PubMed, bioRxiv) - "In our preliminary study, we explored the potential of gadoterate meglumine (Gd-DOTA, a macrocyclic Gd-contrast) in combination with amine chemical-exchange saturation transfer (amine-CEST) imaging to differentiate tumor from radiation necrosis by assessing Gd-DOTA uptake by infiltrating immune cells, such as macrophages...This straightforward imaging approach holds promise for clinical translation. It offers a novel method for characterizing pseudo-progressive lesions and monitoring diverse treatment responses in cancer patients using standard clinical scanners."

IO biomarker • Journal • Oncology

FUS-AD: Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Columbia University | Trial completion date: Dec 2027 ➔ Dec 2028 | Trial primary completion date: Jul 2027 ➔ Jul 2028

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Assessing the impact of Dotarem (a gadolinium-based contrast agent) on the clam Ruditapes decussatus: a multibiomarker approach. (PubMed, Environ Geochem Health) - "Histopathological analyses revealed lesions in both organs, including cellular infiltrations, vacuolization, and necrosis, with severity increasing with DOTA concentration. Overall, this study highlights that Dotarem acts as a significant environmental contaminant, affecting multiple physiological and biochemical processes in R. decussatus, and emphasizes the need to monitor emerging contaminants in aquatic ecosystems."

Biomarker • Journal • Pain • CAT

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis (clinicaltrials.gov) - P2 | N=15 | Recruiting | Sponsor: Peter Caravan

New P2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (clinicaltrials.gov) - P3 | N=315 | Not yet recruiting | Sponsor: Guerbet

Trial initiation date • Cardiovascular

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: Guerbet | N=130 ➔ 300

Enrollment change • Cardiovascular

Collagen-targeted PET Imaging for Early Interstitial Lung Disease (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Massachusetts General Hospital | Trial completion date: Apr 2026 ➔ Dec 2026 | Trial primary completion date: Apr 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance (clinicaltrials.gov) - P=N/A | N=120 | Completed | Sponsor: The Methodist Hospital Research Institute | Unknown status ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Coronary Artery Disease

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease (clinicaltrials.gov) - P3 | N=130 | Not yet recruiting | Sponsor: Guerbet | N=40 ➔ 130

Enrollment change • Cardiovascular

GDX-102/GDX-44-017: Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the assessment of steno-occlusive disease in adult patients with suspected vascular disease (clinicaltrialsregister.eu) - P2/3 | N=40 | Not yet recruiting | Sponsor: Guerbet, Bracco Imaging S.p.A.

New P2/3 trial • Cardiovascular

Cerebral Accumulation of Gadolinium (Gd3+) and Related Cellular Stress Pathways in Rat Brain Tissue. (PubMed, Tomography) - "Linear and macrocyclic GBCAs demonstrated distinct patterns of cerebral Gd3+ accumulation and UPR levels in rats. Accordingly, GBCA administration should be reserved for instances where it is necessary, such as when contrast enhancement is clinically required."

Journal • Preclinical • ATF6 • DDIT3 • ERN1 • PERK

Efficacy of a Novel Dimeric Macrocyclic Gadolinium Chelate With High Relaxivity in Preclinical Models of Neurological and Oncological Pathologies. (PubMed, Invest Radiol) - "Digadoglucitol shows high diagnostic efficacy in preclinical models of neurological and oncological diseases. It delivers comparable effectiveness at half the dose and superior contrast enhancement at the full standard dose compared with established GBCAs. These preclinical findings suggest that digadoglucitol is a promising contrast agent to be considered for clinical translation, potentially allowing for reduced dosage while maintaining or improving diagnostic accuracy."

Journal • Preclinical • Brain Cancer • Breast Cancer • Cardiovascular • Genito-urinary Cancer • Glioma • Hepatology • Meningioma • Oncology • Solid Tumor

Dotarem vs Gadobutrol Contrast for Breast MRI (clinicaltrials.gov) - P4 | N=300 | Completed | Sponsor: University of Massachusetts, Worcester | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Dec 2025

Trial completion • Trial completion date

Synthesis, Stability, and Relaxivity Measurement of Gd (III) Complexes of DOTA Ligands Derived from Amino Acids. (PubMed, Chem Pharm Bull (Tokyo)) - "In plasma, the half-lives of the Gd-DOTA-peptide contrast agents exceeded 5 h. Relaxation experiments revealed that the Gd-DOTA-peptide achieved a slightly higher relaxation rate compared with the commercial agent Dotarem. Therefore, the amino acid modularize modification on the gadolinium-based MRI contrast agents were effective and worthy of further investigation."

Journal • Hematological Disorders

FSJD-GadoCor-2025: Improving Heart Scans in Children: A Study Comparing Two Contrast Agents for MRI (clinicaltrialsregister.eu) - P2/3 | N=30 | Not yet recruiting | Sponsor: Fundacio Sant Joan De Deu

New P2/3 trial • Cardiomyopathy • Cardiovascular • Heart Failure